Uncategorized
Embedding Regulatory Strategy in Cell and Gene Therapy Development
Jeffrey Mocny, PhD
VP Scientific Leadership
Rose BioSolutions
Panelist
Jeffrey Mocny, PhD
Jeffrey Mocny, PhD, VP Scientific Leadership for Rose BioSolutions translates client needs into actionable development and manufacturing programs that help clients achieve their therapeutic development goals. Mocny leads a team of scientists with expertise in cell and molecular biology, virology, immunology, immunotherapy, T-cell biology, and viral vector transduction techniques. Central to the Scientific Leadership team’s approach is developing phase-appropriate strategies that ensure regulatory compliance and provide the scientific rationale for the manufacturing approaches employed by Rose’s clients. A product strategy and development executive leader, he leverages experience in quality management, strategic planning, and risk mitigation to guide programs from conceptualization to completion. Mocny has a PhD from the State University of New York at Buffalo (SUNY at Buffalo), an MS and BS from Gannon University, and has completed postdoctoral fellowships at the University of North Carolina at Chapel Hill and Duke University. As an innovator in the CDMO and CRO sectors for more than 20 years, his experience in product development spans analytical, manufacturing, market entry/positioning, and regulatory strategy.
Felicia Irons, BS, CSSGB
Global CDMO Regulatory Affairs & Compliance Lead
Rose BioSolutions
Panelist
Felicia Irons, BS, CSSGB
Felicia Irons, global CDMO regulatory affairs & compliance lead for Rose BioSolutions, ensures the highest level of quality, regulatory compliance and safety are adhered to for cell and gene therapy programs across Rose BioSolutions CDMO business unit. An expert in Quality Management Systems (QMS), Felicia is a member of the Regulatory Affairs Professionals Society (RAPS), American Society of Quality (ASQ), and Parenteral Drug Association (PDA). Prior to her position at Rose BioSolutions, Felicia served as the global CDMO regulatory affairs & compliance lead for Charles River Laboratories’ CDMO business unit, head of quality at Natureplex, quality manager and regulatory liaison for PharMEDium Services (an AmerisourceBergen company), and corporate quality manager with Drexel Chemical. Felicia has a BS in chemistry and biochemistry from the University of Memphis, certification in Six Sigma Green Belt from Villanova University and certificate in quality culture and investigations from PDA. Active in her community with many organizations involving healthcare, education and youth, Felicia founded the JusLuv Community Foundation in 2006 to assist youth and young adults in career mentorship.
- Time:
For cell and gene therapy programs, early development decisions can have a significant impact on regulatory success, development timelines, and overall program risk. Embedding regulatory strategy from the outset helps developers identify critical challenges early, align development activities with product-specific requirements, and build a stronger foundation for future clinical and commercial milestones.
In this GEN webinar, experts from Rose BioSolutions, a CDMO and Cell Solutions organization formed from Charles River Laboratories’ businesses, will discuss how integrating regulatory strategy at the earliest stages of development can reduce overall risk and improve program outcomes. Attendees will learn how a well-defined Target Product Profile (TPP) can guide decision-making across the drug development lifecycle, and help teams prioritize activities, anticipate regulatory expectations, and develop a fit-for-purpose CGT manufacturing and testing strategy. Presenters will use real-world case studies to highlight common cell and gene therapy product development challenges and practical approaches to addressing issues such as sterility testing, interim product release, and device compatibility at patient infusion.
Key Takeaways
- How to implement a regulatory strategy during program scoping to align development activities with product-specific risks and compliance expectations
- Why a Target Product Profile (TPP) should be established at the beginning of development and how it guides strategy, critical quality requirements, and risk mitigation plans
- How early identification of product-specific challenges can help minimize unnecessary regulatory information requests, avoid manufacturing delays, and support timely patient treatment
- Practical strategies for developing a more efficient, inspection-ready path from early development through clinical manufacturing and commercialization
A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.
Produced with support from:
The post Embedding Regulatory Strategy in Cell and Gene Therapy Development appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized6 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read
